Bristol Myers Squibb (BMY) ended the recent trading session at $56.81, demonstrating a -0.58% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.16%.

The stock market saw something incredible in 2024, with the “Magnificent 7” tech giants leading the charge and driving a huge ...

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we ...

Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, ...

First Hawaiian Bank raised its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.5% during the 4th quarter, ...

Truist raised the firm’s price target on Bristol Myers (BMY) to $65 from $62 and keeps a Buy rating on the shares as part of a broader research ...

Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...

Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $56.57 which represents a decrease of $-0.22 or -0.39% from the prior close of $56.79. The stock opened at $56.34 and touched a low ...

Short BMY slightly under 59.95, target 53.71, stop loss @ 60.12 Check the time stamp on this data. Updated AI-Generated ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other stocks. As retirement approaches, ensuring financial stability becomes ...

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research ...